stars 1 stars 2 stars 3

Fidelta combines expertise in chemistry, pharmacology, ADME, pharmacokinetics and toxicology offering integrated and stand-alone discovery services to the biotech, pharmaceutical, agrochemical, food, cosmetic and chemical industries. Integrated drug discovery is driven by our determination to deliver EFFICACIOUS, SAFE and DIFFERENTIATED preclinical candidates building upon: • Extensive experience in drug discovery, from target validation to early preclinical development • Full range of in-house capabilities including chemistry, pharmacology, ADME, pharmacokinetics and toxicology • Therapeutic area key expertise in inflammation and infection (as well as linked conditions in the fields of oncology and metabolic disease) • Strong emphasis on translational science, focusing on patients and disease-relevant test models/systems Specialities: • extensive AAALAC accredited in vivo capabilities giving the possibility to take projects all the way to the clinic • models of bacterial infections (Sepsis, Thigh infection, RTI, UTI..). We have established relationships with clinical centers that ensure access to recent and clinically relevant Gram-positive and Gram-negative pathogens • unique Macrocyclic library For more information visit our web page www.fidelta.eu or see the company video at: http://vimeo.com/88249298

Fidelta Questions

The Fidelta annual revenue was $20.8 million in 2026.

8 people are employed at Fidelta.

The NAICS codes for Fidelta are [5417, 541, 54, 54171, 541713].

The SIC codes for Fidelta are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users